IDiyas

For the Inventor, By the Inventor

Barcelona, Spain

Minoryx Therapeutics S.l.


USPTO Granted Patents = 9



Trademarks = 4

Forward Citations = 16

Loading Chart...
Loading Chart...

28 inventors (with patents filed for the assignee):

goldMedal Ana Maria García Collazo (6 out of 6 patents)

silverMedal Marc Martinell Pedemonte (5 out of 18 patents)

bronzeMedal Maria Pilar Pizcueta Lalanza (4 out of 5 patents)

4.  Xavier Barril Alonso (3 out of 4 patents)

5.  Elena Cubero Jordà (3 out of 3 patents)

6.  Marc Revés Vilaplana (2 out of 2 patents)

7.  Richard Spurring Roberts (2 out of 4 patents)

8.  Johannes B M Rewinkel (2 out of 2 patents)

9.  Sander De Wilde (2 out of 4 patents)

10.  Wolter Ten Hoeve (2 out of 24 patents)

11.  Johannes Nicolaas Koek (2 out of 5 patents)

12.  David John Augustus Eckland (2 out of 2 patents)

13.  Laura Pilar Rodríguez Pascau (2 out of 2 patents)

14.  Ana María García Collazo (1 out of 1 patent)

15.  Laura Pilar RODRÍGUEZ Pascau (0 patent)


9 patents:

1. 11957670 - 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases (2024-04-16),
2. 11938122 - 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3- thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease (2024-03-26),
3. 11739072 - Heteroaryl compounds and their use (2023-08-29),
4. 11731963 - Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]-methyl]-2,4-thiazolidinedione and salts thereof (2023-08-22),
5. 11440898 - Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase (2022-09-13),
6. 11174242 - Heteroaryl compounds and their use (2021-11-16),
7. 11124505 - Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof (2021-09-21),
8. 10179126 - 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders (2019-01-15),
9. 9782395 - 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders (2017-10-10),
Minoryx Therapeutics is a clinical stage biotech company developing new therapies for rare diseases. They focus on CNS diseases with high unmet medical needs. Their leading product candidate is being developed for adrenomyeloneuropathy and is currently in Phase 2/3 clinical trial.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

9 Patents

#66 in Barcelona

#230 in Spain

...
Barcelona, Spain

Minoryx Therapeutics S.l.

Forward Citations = 16

28 inventors:

goldMedal Ana Maria García Collazo (6 out of 6 patents)

silverMedal Marc Martinell Pedemonte (5 out of 18 patents)

bronzeMedal Maria Pilar Pizcueta Lalanza (4 out of 5 patents)

4.  Xavier Barril Alonso (3 out of 4 patents)

5.  Elena Cubero Jordà (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com
Loading…